目次

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 LIST OF ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.4 FORECASTING TECHNIQUES
3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.5.1 BOTTOM-UP APPROACH
3.5.2 TOP-DOWN APPROACH
3.6 DATA TRIANGULATION
3.7 VALIDATION

4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES
4.2.2 GROWING NUTRITIONAL DEFICIENCY AMONG PEOPLE
4.2.3 RAISING AWARENESS ABOUT PREBIOTICS AND PROBIOTIC PRODUCTS
4.3 RESTRAINTS
4.3.1 LACK OF AWARENESS REGARDING MEDICAL FOOD
4.4 OPPORTUNITIES
4.4.1 INCREASING PRODUCT LAUNCH INITIATIVES AND CONSTANT INNOVATIONS IN DEVELOPING PRODUCTS

5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL MEDICAL FOODS MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON PRODUCTION
5.3.3 IMPACT ON MARKET PLAYERS

6 GLOBAL MEDICAL FOODS MARKET, BY NUTRITIONAL INGREDIENTS
6.1 OVERVIEW
6.2 VITAMINS AND MINERALS
6.3 PROTEINS
6.4 OMEGA-3
6.5 ISOFLAVONES
6.6 PHYTOSTEROLS
6.7 OTHERS

7 GLOBAL MEDICAL FOODS MARKET, BY ROUTE OF ADMINISTRATION
7.1 OVERVIEW
7.2 ORAL
7.3 ENTERAL

8 GLOBAL MEDICAL FOODS MARKET, BY FORM
8.1 OVERVIEW
8.2 PILLS
8.3 POWDER
8.4 OTHERS

9 GLOBAL MEDICAL FOODS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 CHRONIC KIDNEY DISEASE
9.3 NUTRITIONAL DEFICIENCY
9.4 NEUROLOGICAL & PSYCHOLOGICAL DISORDERS
9.5 METABOLIC DISORDERS
9.6 PAIN MANAGEMENT
9.7 GASTROINTESTINAL DISORDERS
9.8 ORPHAN DISEASES
9.9 OTHERS

10 GLOBAL MEDICAL FOODS MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 E-COMMERCE
10.3 HOSPITAL PHARMACIES
10.4 RETAIL PHARMACIES
10.5 OTHERS

11 MEDICAL FOODS MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 US
11.2.2 CANADA
11.3 EUROPE
11.3.1 GERMANY
11.3.2 UK
11.3.3 FRANCE
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 JAPAN
11.4.2 CHINA
11.4.3 INDIA
11.4.4 SOUTH KOREA
11.4.5 AUSTRALIA
11.4.6 REST OF ASIA-PACIFIC
11.5 REST OF THE WORLD
11.5.1 MIDDLE EAST
11.5.2 AFRICA
11.5.3 LATIN AMERICA

12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 COMPETITIVE BENCHMARKING
12.3 MAJOR GROWTH STRATEGY IN THE GLOBAL MEDICAL FOODS MARKET
12.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL MEDICAL FOODS MARKET
12.5 KEY DEVELOPMENT ANALYSIS
12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
12.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
12.6.2 MERGER/ACQUISITION
12.6.3 EXPANSION/ INVESTMENT
12.7 MAJOR PLAYERS SALES ANALYSIS
12.8 MAJOR PLAYERS R&D ANALYSIS

13 COMPANY PROFILES
13.1 DANONE SA
13.1.1 COMPANY OVERVIEW
13.1.2 FINANCIAL OVERVIEW
13.1.3 PRODUCTS OFFERED
13.1.4 KEY DEVELOPMENTS
13.1.5 SWOT ANALYSIS
13.1.6 KEY STRATEGIES
13.2 ABBOTT
13.2.1 COMPANY OVERVIEW
13.2.2 FINANCIAL OVERVIEW
13.2.3 PRODUCTS OFFERED
13.2.4 KEY DEVELOPMENTS
13.2.5 SWOT ANALYSIS
13.2.6 KEY STRATEGIES
13.3 FRESENIUS KABI AG
13.3.1 COMPANY OVERVIEW
13.3.2 PRODUCTS OFFERED
13.3.3 KEY DEVELOPMENTS
13.3.4 SWOT ANALYSIS
13.3.5 KEY STRATEGIES
13.4 TARGETED MEDICAL PHARMA INC
13.4.1 COMPANY OVERVIEW
13.4.2 FINANCIAL OVERVIEW
13.4.3 PRODUCTS OFFERED
13.4.4 KEY DEVELOPMENTS
13.4.5 KEY STRATEGIES
13.5 METAGENICS LLC
13.5.1 COMPANY OVERVIEW
13.5.2 FINANCIAL OVERVIEW
13.5.3 PRODUCTS OFFERED
13.5.4 KEY DEVELOPMENTS
13.5.5 KEY STRATEGIES
13.6 NESTLÉ
13.6.1 COMPANY OVERVIEW
13.6.2 FINANCIAL OVERVIEW
13.6.3 PRODUCTS OFFERED
13.6.4 KEY DEVELOPMENTS
13.6.5 SWOT ANALYSIS
13.6.6 KEY STRATEGIES
13.7 RECKITT BENCKISER GROUP PLC
13.7.1 COMPANY OVERVIEW
13.7.2 FINANCIAL OVERVIEW
13.7.3 PRODUCTS OFFERED
13.7.4 KEY DEVELOPMENTS
13.7.5 SWOT ANALYSIS
13.7.6 KEY STRATEGIES
13.8 MEDTRITION, INC
13.8.1 COMPANY OVERVIEWS
13.8.2 FINANCIAL OVERVIEW
13.8.3 PRODUCTS OFFERED
13.8.4 KEY DEVELOPMENTS
13.8.5 KEY STRATEGIES
13.9 PRIMUS PHARMACEUTICALS, INC
13.9.1 COMPANY OVERVIEW
13.9.2 FINANCIAL OVERVIEW
13.9.3 PRODUCTS OFFERED
13.9.4 KEY DEVELOPMENTS
13.9.5 KEY STRATEGIES
13.10 ALFASIGMA USA, INC
13.10.1 COMPANY OVERVIEW
13.10.2 FINANCIAL OVERVIEW
13.10.3 PRODUCTS OFFERED
13.10.4 KEY DEVELOPMENTSS
13.10.5 KEY STRATEGIES

14 APPENDIX
14.1 REFERENCES
14.2 RELATED REPORTS